A Study of LP-118 in Patients With Advanced Tumors
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety,
tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced
malignancies, including solid tumors and B-cell lymphomas. LP-118 is a BCL-2/BCL-XL small
molecule inhibitor.